BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 11, 2005
View Archived Issues
Promising results with oral FXa inhibitor BAY-59-7939 reported at ISTH meeting
Read More
SB-497115 increases platelet counts in healthy volunteers
Read More
Pfizer makes strides in Q2
Read More
Speedel boosts pipeline development with private funding round
Read More
Neose Technologies to restructure operations
Read More
GlycoGenesis lays out plans for development of GCS-100
Read More
Novel NHE-1 inhibitor demonstrates preclinical cardioprotection
Read More
NCX-6550 elicits superior antithrombosis and antiatherogenesis effects
Read More
Tarceva sNDA for pancreatic cancer to be reviewed in September
Read More
Tysabri safety evaluation update
Read More
First melanoma patients complete treatment in phase I study of PV-10
Read More
Neurocrine Biosciences presents data on CRF-1 antagonist NBI-35965
Read More
Positive findings for bosentan in systemic sclerosis patients
Read More
Further investigation of orally active FXa inhibitor razaxaban
Read More
Dosing completed in phase II study of HepeX-B
Read More
European authorities approve phase III studies of Japanese encephalitis vaccine
Read More
BCX-4208 enters phase Ib study
Read More
Fodosine begins phase I pharmacokinetic study
Read More
NexMed updates status of lead programs
Read More
Update on tacrolimus ointment in the treatment of atopic dermatitis
Read More
Promising results reported for TRX-4 in type 1 diabetes
Read More
Recent patents cover novel antidepressants
Read More
Recent patents cover novel treatments for neurological disorders
Read More
Prodrug SERMs prepared and tested at GlaxoSmithKline
Read More
Novel therapeutics for cardiovascular diseases reported
Read More